UNIV CA LOS ANGELES
PharmaUNIV CA LOS ANGELES is a pharmaceutical company focused on Oncology. Key products include GALLIUM GA 68 GOZETOTIDE.
UNIV CA LOS ANGELES's Key Drugs
UNIV CA LOS ANGELES's core commercial portfolio centers on GALLIUM GA 68 GOZETOTIDE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
UNIV CA LOS ANGELES's Recent FDA Approvals
New NDA/BLA approvals for UNIV CA LOS ANGELES over the last two years — novel drugs only, excluding generics and label supplements.
UNIV CA LOS ANGELES's Therapeutic Areas
UNIV CA LOS ANGELES's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UNIV CA LOS ANGELES's Top Competitors
UNIV CA LOS ANGELES's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UNIV CA LOS ANGELES Pipeline Snapshot
Active clinical trials for UNIV CA LOS ANGELES across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GALLIUM GA 68 GOZETOTIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-12-01
- Latest
- 2022-06-16
- Applications
- 1